Patents by Inventor Vadim Kraynov

Vadim Kraynov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic uses of modified relaxin polypeptides
    Patent number: 10253083
    Abstract: Therapeutic uses of modified relaxin polypeptides for the treatment of cardiovascular disease, treatment of heart failure, and decreasing fibrotic disorders are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 9, 2019
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Bovine G-CSF Polypeptides And Their Uses
    Publication number: 20190071482
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: March 7, 2019
    Inventors: Anna-Maria A. HAYS PUTNAM, Nick KNUDSEN, Thea NORMAN, Alan KODER, Vadim KRAYNOV, Lillian HO, Peter C. CANNING
  • Modified bovine G-CSF polypeptides and their uses
    Patent number: 10138283
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 27, 2018
    Assignees: AMBRX, INC., ELANCO US INC.
    Inventors: Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Ho, Peter C. Canning
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20180311368
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: March 30, 2018
    Publication date: November 1, 2018
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES
    Publication number: 20180298073
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
  • Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9975936
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 22, 2018
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Method of treating heart failure with modified relaxin polypeptides
    Patent number: 9962450
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 8, 2018
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified leptin polypeptides and their uses
    Patent number: 9938333
    Abstract: Modified human leptin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: April 10, 2018
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Anna-Maria A. Hays Putnam, Nick Knudsen, Jason Pinkstaff, Heather Myler, Lorraine Sullivan
  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20180009845
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 11, 2018
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei Maio, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jaosn Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Lanina Lopez De Valenta
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 9796754
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: October 24, 2017
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES
    Publication number: 20170226178
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 10, 2017
    Inventors: VADIM KRAYNOV, NICK KNUDSEN, AMHA HEWET, KRISTINE DE DIOS, JASON PINKSTAFF, LORRAINE SULLIVAN
  • Modified FGF-21 Polypeptides and Their Uses
    Publication number: 20170096463
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 6, 2017
    Inventors: Thomas P. CUJEC, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Therapeutic uses of modified relaxin polypeptides
    Patent number: 9567386
    Abstract: Modified relaxin polypeptides and their uses, including therapeutic uses thereof for the treatment of a fibrotic disorder or heart failure are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 14, 2017
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine de Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20170035897
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: August 17, 2016
    Publication date: February 9, 2017
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9517273
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: December 13, 2016
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Nucleic acids encoding modified relaxin polypeptides
    Patent number: 9452222
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: September 27, 2016
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives
    Publication number: 20160052966
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: May 24, 2012
    Publication date: February 25, 2016
    Applicant: AMBRX, INC.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun
  • Modified Insulin Polypeptides and Their Uses
    Publication number: 20150299288
    Abstract: Modified insulin polypeptides and their uses thereof are provided
    Type: Application
    Filed: December 19, 2014
    Publication date: October 22, 2015
    Applicant: AMBRX, INC.
    Inventors: Zhenwei MIAO, Denise KRAWITZ, Vadim KRAYNOV, Tian FENG, Bee-Cheng SIM, Lillian SKIDMORE, Anna-Maria A. HAYS PUTNAM, Nick KNUDSEN, Michael DEGUZMAN
  • THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY OCCURRING AMINO ACIDS
    Publication number: 20150273075
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 1, 2015
    Inventors: Thomas P. CUJEC, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9079971
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: July 14, 2015
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Ho, Jason Pinkstaff, Vadim Kraynov